Search
Research
Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 comparedPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
Breastfeeding patterns and total volume of human milk consumed influence the development of the infant oral microbiomeThe oral microbiome of breastfed infants is distinct from that of formula-fed infants. However, breastfeeding characteristics, such as time spent breastfeeding (min/24 h), breastfeeding frequency (number of breastfeeds per day), and human milk intake (ml/day) vary significantly between breastfeeding dyads.
A unique initiative is combining research, action and advocacy to deliver evidence- based improvements to the health and wellbeing of Aboriginal families in Perth and Western Australia’s north west.
Three hundred and fifty million people live with an undiagnosed disease worldwide and three quarters of them are children.
Flow cytometry is a technology used to measure complex cell phenotype and functions. Our Flow Facility is equipped with 3 flow cytometers/analysers, one...
An Australian-first study, funded by Perth Children's Hospital Foundation, demonstrating the effectiveness of a new immunisation against respiratory syncytial virus (RSV) for babies found it to be almost 90 per cent effective in reducing hospitalisation rates.
Alarming statistics laying bare the social emotional wellbeing and mental health challenges facing Aboriginal and Torres Strait Islander LGBTQA+ youth are driving a multi-partner program to provide them with greater support.
The Kids Research Institute Australia is at the forefront of a global effort to track and prevent malaria – one of the world’s leading causes of disease and child deaths, particularly in developing countries.
Research
Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age- and seasonally-targeted deliveryThe World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.
Research
Value profile for Malaria vaccines and monoclonal antibodies1Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children.